PMID- 22111044
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111123
LR  - 20211021
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 35
IP  - 5
DP  - 2011 Oct
TI  - Serum visfatin and fetuin-a levels and glycemic control in patients with obese 
      type 2 diabetes mellitus.
PG  - 523-8
LID - 10.4093/dmj.2011.35.5.523 [doi]
AB  - BACKGROUND: Visfatin is an adipokine produced by visceral adipose tissue and has 
      insulin-mimicking effects. Fetuin-A is a hepatic secretory protein that binds the 
      insulin receptor and inhibits insulin action both in vivo and in vitro. The 
      authors of the present study aimed to investigate the levels of serum visfatin 
      and fetuin-A and their correlation with hemoglobin A1c (HbA1c) and urine albumin 
      levels in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 40 
      obese patients with T2DM (11 males and 29 females; age, 54.47+/-10.83 years and 23 
      obese nondiabetic controls (8 males and 15 females; age, 53.04+/-11.33 years) were 
      included in the study. Age, sex, and body mass index were similar in the 2 
      groups. Serum visfatin and fetuin-A levels were measured by enzyme-linked 
      immunosorbent assay. HbA1c and urine albumin levels were measured by high 
      performance liquid chromatography and nephelometric method, respectively. 
      RESULTS: Serum levels of visfatin in patients with T2DM (4.03+/-2.44 ng/mL) were 
      similar to the control group (3.65+/-3.02 ng/mL). Serum fetuin-A levels were 
      significantly lower in patients with T2DM than the controls (298.75+/-78.86 and 
      430.73+/-94.46 microg/mL, respectively). HbA1c levels were significantly higher in the 
      T2DM group compared with controls (7.33+/-1.32 and 5.44+/-0.84%, respectively). 
      Correlations between visfatin, fetuin-A and HbA1c levels were not observed. 
      CONCLUSION: The present study suggests fetuin-A may play a role in the 
      pathogenesis of T2DM.
FAU - Gunduz, Fethiye Oztop
AU  - Gunduz FO
AD  - Department of Clinical Biochemistry, Okmeydani Educational and Research Hospital, 
      Istanbul, Turkey.
FAU - Yildirmak, Sembol Turkmen
AU  - Yildirmak ST
FAU - Temizel, Mustafa
AU  - Temizel M
FAU - Faki, Yilmaz
AU  - Faki Y
FAU - Cakmak, Mustafa
AU  - Cakmak M
FAU - Durmuscan, Mustafa
AU  - Durmuscan M
FAU - Sezgin, Funda
AU  - Sezgin F
LA  - eng
PT  - Journal Article
DEP - 20111031
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3221028
OTO - NOTNLM
OT  - Albuminuria
OT  - Diabetes mellitus, type 2
OT  - Fetuin-A
OT  - Hemoglobin A1c
OT  - Visfatin
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2011/11/24 06:00
MHDA- 2011/11/24 06:01
PMCR- 2011/10/01
CRDT- 2011/11/24 06:00
PHST- 2010/11/25 00:00 [received]
PHST- 2011/05/02 00:00 [accepted]
PHST- 2011/11/24 06:00 [entrez]
PHST- 2011/11/24 06:00 [pubmed]
PHST- 2011/11/24 06:01 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - 10.4093/dmj.2011.35.5.523 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2011 Oct;35(5):523-8. doi: 10.4093/dmj.2011.35.5.523. Epub 2011 
      Oct 31.